Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

A Corrigendum to this article was published on 11 October 2007

Abstract

Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients (n=114; 228 specimen) by GeneChip and quantitative real-time RT–PCR, identifies ETS-related gene (ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen (54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, Caligiuri MA, Bloomfield CD and de la Chapelle A . (2004). Proc. Natl. Acad. Sci. USA, 101, 3915–3920.

  • Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB . (1999). Cancer Res., 59, 5975–5979.

  • Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM . (2001). Nature, 412, 822–826.

  • Gavrilov D, Kenzior O, Evans M, Calaluce R and Folk WR . (2001). Eur. J. Cancer, 37, 1033–1040.

  • Gelmann EP . (2003). Crit. Rev. Oncol. Hematol., 46 (Suppl.), S11–S20.

  • Hart AH, Corrick CM, Tymms MJ, Hertzog PJ and Kola I . (1995). Oncogene, 10, 1423–1430.

  • Hsu T, Trojanowska M and Watson DK . (2004). J. Cell Biochem., 91, 896–903.

  • Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM and Staudt LM . (2004). Cancer Cell, 5, 191–199.

  • Isaacs W and Kainu T . (2001). Epidemiol. Rev., 23, 36–41.

  • Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS and Hood L . (1997). Prostate, 30, 145–153.

  • Nelson WG, de Marzo AM and Isaacs WB . (2003). N. Engl. J. Med., 349, 366–381.

  • Oikawa T and Yamada T . (2003). Gene, 303, 11–34.

  • Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K, Shimizu N, Kola I and Hertzog PJ . (2004). Gene, 324, 65–77.

  • Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S . (2004). Oncogene, 23, 605–611.

  • Reddy ES, Rao VN and Papas TS . (1987). Proc. Natl. Acad. Sci. USA, 84, 6131–6135.

  • Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D and Chinnaiyan AM . (2002). JAMA, 287, 1662–1670.

  • Sementchenko VI, Schweinfest CW, Papas TS and Watson DK . (1998). Oncogene, 17, 2883–2888.

  • Srikantan V and Srivastava S . (2003). Prostate Cancer. Hofmann R, Heidenreich A, Moul JW (eds) Springer-Verlag: Berlin, pp 25–40.

Download references

Acknowledgements

The prostate tissue specimens used in this study were obtained under an IRB-approved protocol at Walter Reed Army Medical Center. Informed consent was obtained from each subject. We thank DK Watson for providing ERG1 and ERG2 cDNA clones and for critically reading the manuscript. This work was funded by the CPDR through an ongoing grant from the US Army Medical Research and Materiel Command and by NIH Grant RO1 DK065977 to SS. None of the authors have competing financial interests. The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the official views of the US Army or the Department of Defense.

Author information

Authors and Affiliations

Authors

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrovics, G., Liu, A., Shaheduzzaman, S. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005). https://doi.org/10.1038/sj.onc.1208518

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208518

Keywords

This article is cited by

Search

Quick links